Safety concerns of angiotensin II receptor blockers in preschool children - PubMed

Safety concerns of angiotensin II receptor blockers in preschool children

Kjell Tullus. Arch Dis Child. 2011 Sep.

Abstract

Two recent trials of angiotensin II receptor blockers (ARBs) were performed in children 0-5 years of age. Data from the published reports of these trials together with additional information from the sponsoring drug companies were obtained. Three deaths occurred in the 183 (1.6%) hypertensive children participating in the two trials. At least two of these deaths occurred in children known to be susceptible to drugs acting on the renin-angiotensin system, that is, children with ongoing nephrotic syndrome and acute gastroenteritis. Clinicians who prescribe ARBs in preschool children need to be aware of the risk of drug toxicity especially in children susceptible to intravascular dehydration. Clinicians should consider discontinuing the drugs in the presence of acute diarrhoea.

Comment in

• Safety of new medicines in young children.

  Choonara I. Choonara I. Arch Dis Child. 2011 Sep;96(9):872-3. doi: 10.1136/archdischild-2011-300450. Arch Dis Child. 2011. PMID: 21836178 Free PMC article. No abstract available.

Similar articles

• Angiotensin receptor blockers and myocardial infarction.

  Verma S, Strauss M. Verma S, et al. BMJ. 2004 Nov 27;329(7477):1248-9. doi: 10.1136/bmj.329.7477.1248. BMJ. 2004. PMID: 15564232 Free PMC article. No abstract available.

• Angiotensin receptor blockers and myocardial infarction: the importance of dosage.

  Sarzani R, Dessì-Fulgheri P. Sarzani R, et al. J Hypertens. 2006 Aug;24(8):1679-81; author reply 1681-2. doi: 10.1097/01.hjh.0000239307.86248.80. J Hypertens. 2006. PMID: 16877973 No abstract available.

• Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.

  Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D. Bos-Thompson MA, et al. Ann Pharmacother. 2005 Jan;39(1):157-61. doi: 10.1345/aph.1E250. Epub 2004 Dec 8. Ann Pharmacother. 2005. PMID: 15590878 Review.

• Aliskiren/valsartan (Valturna) for hypertension.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Nov 30;51(1326):94-5. Med Lett Drugs Ther. 2009. PMID: 20224524 Review. No abstract available.

Cited by

• IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

  Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Müller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D; International Pediatric Nephrology Association. Trautmann A, et al. Pediatr Nephrol. 2020 Aug;35(8):1529-1561. doi: 10.1007/s00467-020-04519-1. Epub 2020 May 7. Pediatr Nephrol. 2020. PMID: 32382828 Free PMC article. Review.

• Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.

  Terano C, Ishikura K, Miura M, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Ando T, Honda M. Terano C, et al. Eur J Pediatr. 2016 May;175(5):631-7. doi: 10.1007/s00431-015-2680-8. Epub 2015 Dec 21. Eur J Pediatr. 2016. PMID: 26687571

• Chapter 6: Blood pressure management in children with CKD ND.

  [No authors listed] [No authors listed] Kidney Int Suppl (2011). 2012 Dec;2(5):372-376. doi: 10.1038/kisup.2012.56. Kidney Int Suppl (2011). 2012. PMID: 25018965 Free PMC article. No abstract available.

• When should we start and stop ACEi/ARB in paediatric chronic kidney disease?

  Chan EY, Ma AL, Tullus K. Chan EY, et al. Pediatr Nephrol. 2021 Jul;36(7):1751-1764. doi: 10.1007/s00467-020-04788-w. Epub 2020 Oct 14. Pediatr Nephrol. 2021. PMID: 33057769 Review.

• Educational Paper: Aspects of clinical pharmacology in children--pharmacovigilance and safety.

  Choonara I. Choonara I. Eur J Pediatr. 2013 May;172(5):577-80. doi: 10.1007/s00431-012-1871-9. Epub 2012 Oct 31. Eur J Pediatr. 2013. PMID: 23111760 Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • HighWire
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information